Sharekhan's research report on Sun Pharmaceutical Industries
Sun Pharma’s specialty business is on a strong footing and traction is expected to improve further backed by rising prescriptions and geographical expansion. Sun Pharma has a strong new product pipeline in the US with 90 ANDAs and 8 NDAs awaiting USFDA approval and growth in the base business would result in healthy growth of the US business. Strong position in the chronic as well as acute therapies, double digit growth expected for IPM and increasing field force productivity and geographic penetration would be the key drivers for the India business.
Outlook
We retain a Buy recommendation on Sun Pharmaceutical Industries (Sun Pharma) with an unchanged PT of Rs. 700.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
